🚀 VC round data is live in beta, check it out!
Laurus Labs Valuation Multiples
Discover revenue and EBITDA valuation multiples for Laurus Labs and similar public comparables like Belite Bio, China Resources Sanjiu, Bachem, Arcellx and more.
Laurus Labs Overview
About Laurus Labs
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
Founded
2005
HQ
Employees
6.2K
Website
Financials (LTM)
EV
$7B
Laurus Labs Financials
Laurus Labs reported last 12-month revenue of $746M and EBITDA of $193M.
In the same LTM period, Laurus Labs generated $447M in gross profit, $193M in EBITDA, and $94M in net income.
Revenue (LTM)
Laurus Labs P&L
In the most recent fiscal year, Laurus Labs reported revenue of $651M and EBITDA of $124M.
Laurus Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $746M | XXX | $651M | XXX | XXX | XXX |
| Gross Profit | $447M | XXX | $319M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $193M | XXX | $124M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $94M | XXX | $41M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $279M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Laurus Labs Stock Performance
Laurus Labs has current market cap of $7B, and enterprise value of $7B.
Market Cap Evolution
Laurus Labs' stock price is $12.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | 0.8% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLaurus Labs Valuation Multiples
Laurus Labs trades at 9.1x EV/Revenue multiple, and 35.3x EV/EBITDA.
EV / Revenue (LTM)
Laurus Labs Financial Valuation Multiples
As of April 19, 2026, Laurus Labs has market cap of $7B and EV of $7B.
Equity research analysts estimate Laurus Labs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laurus Labs has a P/E ratio of 69.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | 35.3x | XXX | 55.1x | XXX | XXX | XXX |
| EV/EBIT | 48.8x | XXX | 91.5x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | 21.4x | XXX | XXX | XXX |
| P/E | 69.8x | XXX | 160.7x | XXX | XXX | XXX |
| EV/FCF | 260.1x | XXX | 2743.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Laurus Labs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Laurus Labs Margins & Growth Rates
Laurus Labs' revenue in the last 12 month grew by 15%.
Laurus Labs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Laurus Labs' rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laurus Labs' rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Laurus Labs Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 55% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Laurus Labs Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Laurus Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Belite Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| China Resources Sanjiu | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcellx | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Allist | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laurus Labs M&A Activity
Laurus Labs acquired XXX companies to date.
Last acquisition by Laurus Labs was on XXXXXXXX, XXXXX. Laurus Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Laurus Labs
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLaurus Labs Investment Activity
Laurus Labs invested in XXX companies to date.
Laurus Labs made its latest investment on XXXXXXXX, XXXXX. Laurus Labs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Laurus Labs
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Laurus Labs
| When was Laurus Labs founded? | Laurus Labs was founded in 2005. |
| Where is Laurus Labs headquartered? | Laurus Labs is headquartered in India. |
| How many employees does Laurus Labs have? | As of today, Laurus Labs has over 6K employees. |
| Who is the CEO of Laurus Labs? | Laurus Labs' CEO is Satyanarayana Chava. |
| Is Laurus Labs publicly listed? | Yes, Laurus Labs is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Laurus Labs? | Laurus Labs trades under LAURUSLABS ticker. |
| When did Laurus Labs go public? | Laurus Labs went public in 2016. |
| Who are competitors of Laurus Labs? | Laurus Labs main competitors are Belite Bio, China Resources Sanjiu, Bachem, Arcellx. |
| What is the current market cap of Laurus Labs? | Laurus Labs' current market cap is $7B. |
| What is the current revenue of Laurus Labs? | Laurus Labs' last 12 months revenue is $746M. |
| What is the current revenue growth of Laurus Labs? | Laurus Labs revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Laurus Labs? | Current revenue multiple of Laurus Labs is 9.1x. |
| Is Laurus Labs profitable? | Yes, Laurus Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laurus Labs? | Laurus Labs' last 12 months EBITDA is $193M. |
| What is Laurus Labs' EBITDA margin? | Laurus Labs' last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Laurus Labs? | Current EBITDA multiple of Laurus Labs is 35.3x. |
| What is the current FCF of Laurus Labs? | Laurus Labs' last 12 months FCF is $26M. |
| What is Laurus Labs' FCF margin? | Laurus Labs' last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Laurus Labs? | Current FCF multiple of Laurus Labs is 260.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.